Of note, our in vitro studies indicated that the concentration of 5-Aza-dC to which AXL-positive cells are sensitive are well within the 5-Aza-dC blood concentrations observed in clinical trials for the treatment of different cancer types (Karahoca and Momparler, 2013). The gene discussed is AXL; the disease is cancer.